BRIEF

on Theranexus (EPA:ALTHX)

Theranexus Strengthens its Treasury and Develops its Partnerships

Stock price chart of Theranexus (EPA:ALTHX) showing fluctuations.

On January 30, 2025, Theranexus announced a cash position of €1.0 million as of December 31, 2024, a decrease from €1.9 million as of September 30, 2024. However, this situation has evolved favorably, with cash reaching €4.0 million as of January 29, 2025. This strengthening is due to a key partnership with Exeltis, which provided an initial payment of €2 million, and to financing from Bpifrance of €1.1 million for the NeuroLead and PickASO projects.

Theranexus, a specialist in rare neurological diseases, is leveraging its partnership with Insud Pharma to market TX01 for Niemann-Pick C and Gaucher diseases. A restructuring of its debt has been agreed with banking partners, including a deferral of repayments. The company is also aiming to launch the pivotal study of its Batten-1 candidate in 2025.

R. P.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Theranexus news